Federal Register / Vol. 74, No. 140 / Thursday, July 23, 2009 / Notices 36511 

(4) Affected public who will be asked 

or required to respond, as well as a brief 

abstract: State agencies, tribal 

governments, local governments, 

colleges and universities, non-profit 

organizations, and for-profit 

organizations. The purpose of the 

Recovery Act solicitation template is to 

provide a framework to develop 

program-specific announcements 

soliciting applications for funding. A 

program solicitation outlines the 

specifics of the funding program; 

describes requirements for eligibility; 

instructs an applicant on the necessary 

components of an application under a 

specific program (e.g., project activities 

and timeline, proposed budget); and 

provides registration dates, due dates, 

and instructions on how to apply within 

the designated application system. 

(5) An estimate of the total number of 

respondents and the amount of time 

estimated for an average respondent to 

respond/reply: It is estimated that 

information will be collected annually 

from 250 applicants, representing State 

agencies, tribal governments, local 

governments, colleges and universities, 

non-profit organizations, and for-profit 

organizations. Annual cost to the 

respondents is based on the number of 

hours involved in preparing and 

submitting a complete application 

package. Public reporting burden for 

this collection of information is 

estimated at up to 30 hours per 

application. The 30-hour estimate is 

based on the amount of time to prepare 

research and evaluation proposals, one 

of the most time intensive types of 

applications solicited by OJP. The 

estimate of burden hours is based on 

OJP’s prior experience with the 

application submission process. 

(6) An estimate of the total public 

burden (in hours) associated with the 

collection: The estimated public burden 

associated with this collection is 7,500 

hours. 

If additional information is required 

contact: Mrs. Lynn Bryant, Department 

Clearance Officer, United States 

Department of Justice, Justice 

Management Division, Policy and 

Planning Staff, Suite 1600, 601 D Street, 

NW., Washington, DC 20530. 

Dated: July 20, 2009. 

Lynn Bryant, 

Department Clearance Officer, PRA, United 

States Department of Justice. 

[FR Doc. E9–17569 Filed 7–22–09; 8:45 am] 

BILLING CODE 4410–18–P 

DEPARTMENT OF JUSTICE 

Office of Justice Programs 

Office of Juvenile Justice and 

Delinquency Prevention 

[OMB Number 1121–0218] 

Agency Information Collection 

Activities: Proposed Collection; 

Comments Requested 

ACTION: 60-Day Notice of Information 

Collection Under Review; Census of 

Juveniles in Residential Placement 

(Reinstatement, without change, of a 

previously approved collection for 

which approval has expired). 

The Department of Justice (DOJ), 

Office of Justice Programs, Office of 

Juvenile Justice and Delinquency 

Prevention, will be submitting the 

following information collection request 

to the Office of Management and Budget 

(OMB) for review and approval in 

accordance with the Paperwork 

Reduction Act of 1995. The proposed 

information collection is published to 

obtain comments from the public and 

affected agencies. Comments are 

encouraged and will be accepted for 

‘‘sixty days’’ until September 21, 2009. 

This process is conducted in accordance 

with 5 CFR 1320.10. 

If you have comments especially on 

the estimated public burden or 

associated response time, suggestions, 

or need a copy of the proposed 

information collection instrument with 

instructions or additional information, 

please contact Janet Chiancone, (202) 

353–9258, Office of Juvenile Justice and 

Delinquency Prevention, Office of 

Justice Programs, U.S. Department of 

Justice, 810 Seventh Street, NW., 

Washington, DC 20531. 

Written comments and suggestions 

from the public and affected agencies 

concerning the proposed collection of 

information are encouraged. Your 

comments should address one or more 

of the following four points: 

—Evaluate whether the proposed 

collection of information is necessary 

for the proper performance of the 

functions of the agency, including 

whether the information will have 

practical utility; 

—Evaluate the accuracy of the agencies 

estimate of the burden of the 

proposed collection of information, 

including the validity of the 

methodology and assumptions used; 

—Enhance the quality, utility, and 

clarity of the information to be 

collected; and 

—Minimize the burden of the collection 

of information on those who are to 

respond, including through the use of 

appropriate automated, electronic, 

mechanical, or other technological 

collection techniques or other forms 

of information technology, e.g., 

permitting electronic submission of 

responses. 

Overview of this information 

collection: 

(1) Type of information collection: 

Extension of previously approved 

collection. 

(2) The title of the form/collection: 

Census of Juveniles in Residential 

Placement. 

(3) The agency form number, if any, 

and the applicable component of the 

Department sponsoring the collection: 

The form number is CJ–14, Office of 

Juvenile Justice and Delinquency 

Prevention, United States Department of 

Justice. 

(4) Affected public who will be asked 

or required to respond, as well as a brief 

abstract: Primary: Federal Government, 

State, Local or Tribal. Other: Not-forprofit institutions; business or other forprofit. 

(5) An estimate of the total number of 

respondents and the amount of time 

estimated for an average respondent to 

respond/reply: It is estimated that 3,500 

respondents will complete a 3-hour 

questionnaire. 

(6) An estimate of the total public 

burden (in hours) associated with the 

collection: Approximately 11,550 hours. 

If additional information is required 

contact: Lynn Bryant, Department 

Clearance Officer, U.S. Department of 

Justice, Justice Management Division, 

Policy and Planning Staff, Patrick Henry 

Building, Suite 1600, 601 D Street NW., 

Washington, DC 20530. 

Dated: July 20, 2009. 

Lynn Bryant, 

Department Deputy Clearance Officer, PRA, 

U.S. Department of Justice. 

[FR Doc. E9–17565 Filed 7–22–09; 8:45 am] 

BILLING CODE 4410–18–P 

DEPARTMENT OF JUSTICE 

Drug Enforcement Administration 

[Docket No. DEA–317R] 

Controlled Substances: Proposed 

Revised Aggregate Production Quotas 

for 2009 

AGENCY: Drug Enforcement 

Administration (DEA), Justice. 

ACTION: Notice of proposed revised 2009 

aggregate production quotas. 

SUMMARY: This notice proposes revised 

2009 aggregate production quotas for 


erowe on DSK5CLS3C1PROD with NOTICES
36512 Federal Register / Vol. 74, No. 140 / Thursday, July 23, 2009 / Notices 

controlled substances in schedules I and 

II of the Controlled Substances Act 

(CSA). 

DATES: Written comments must be 

postmarked, and electronic comments 

must be sent, on or before August 24, 

2009. 

ADDRESSES: To ensure proper handling 

of comments, please reference ‘‘Docket 

No. DEA–317R’’ on all written and 

electronic correspondence. Written 

comments should be sent to the DEA 

Headquarters, Attention: DEA Federal 

Register Representative/ODL, 8701 

Morrissette Drive, Springfield, VA 

22152. Comments may be directly sent 

to DEA electronically by sending an 

electronic message to 

dea.diversion.policy@usdoj.gov. An 

electronic copy of this document is also 

available at the http:// 

www.regulations.gov Web site. 

However, persons wishing to request a 

hearing should note that such requests 

must be written and manually signed; 

requests for a hearing will not be 

accepted via electronic means. DEA will 

accept attachments to electronic 

comments in Microsoft Word, 

WordPerfect, Adobe PDF, or Excel file 

formats only. DEA will not accept any 

file format other than those specifically 

listed here. 

FOR FURTHER INFORMATION CONTACT: 

Christine A. Sannerud, Ph.D., Chief, 

Drug and Chemical Evaluation Section, 

Drug Enforcement Administration, 8701 

Morrissette Drive, Springfield, VA 

22152, or by telephone at (202) 307– 

7183. 

SUPPLEMENTARY INFORMATION: Section 

306 of the CSA (21 U.S.C. 826) requires 

that the Attorney General establish 

aggregate production quotas for each 

basic class of controlled substance listed 

in schedules I and II. This responsibility 

has been delegated to the Administrator 

of the DEA by 28 CFR 0.100. The 

Administrator in turn, has redelegated 

this function to the Deputy 

Administrator, pursuant to 28 CFR 

0.104. 

On November 7, 2008, a notice of 

proposed 2009 aggregate production 

quotas for certain controlled substances 

in schedules I and II was published in 

the Federal Register (73 FR 66256). This 

notice stipulated that the DEA would 

adjust the quotas in 2009 as provided 

for in 21 CFR part 1303. 

The proposed revised 2009 aggregate 

production quotas represent those 

quantities of controlled substances in 

schedules I and II that may be produced 

in the United States in 2009 to provide 

adequate supplies of each substance for: 

The estimated medical, scientific, 

research and industrial needs of the 

United States; lawful export 

requirements; and the establishment 

and maintenance of reserve stocks. 

These quotas do not include imports of 

controlled substances for use in 

industrial processes. 

The proposed revisions are based on 

a review of 2008 year-end inventories, 

2008 disposition data submitted by 

quota applicants, estimates of the 

medical needs of the United States, 

product development, and other 

information available to the DEA. 

Therefore, under the authority vested 

in the Attorney General by Section 306 

of the CSA (21 U.S.C. 826), and 

delegated to the Administrator of the 

DEA by 28 CFR 0.100, and redelegated 

to the Deputy Administrator pursuant to 

28 CFR 0.104, the Deputy Administrator 

hereby proposes the following revised 

2009 aggregate production quotas for the 

following controlled substances, 

expressed in grams of anhydrous acid or 

base: 

Basic class—schedule I 

Previously 

established initial 

2009 quotas 

Proposed revised 

2009 quotas 

2,5-Dimethoxyamphetamine .................................................................................................................... 2 g 2 g 

2,5-Dimethoxy-4-ethylamphetamine (DOET) .......................................................................................... 2 g 2 g 

3-Methylfentanyl ....................................................................................................................................... 2 g 2 g 

3-Methylthiofentanyl ................................................................................................................................. 2 g 2 g 

3,4-Methylenedioxyamphetamine (MDA) ................................................................................................ 25 g 25 g 

3,4-Methylenedioxy-N-ethylamphetamine (MDEA) ................................................................................. 10 g 10 g 

3,4-Methylenedioxymethamphetamine (MDMA) ..................................................................................... 20 g 20 g 

3,4,5-Trimethoxyamphetamine ................................................................................................................ 2 g 2 g 

4-Bromo-2,5-dimethoxyamphetamine (DOB) .......................................................................................... 2 g 2 g 

4-Bromo-2,5-dimethoxyphenethylamine (2–CB) ..................................................................................... 2 g 2 g 

4-Methoxyamphetamine .......................................................................................................................... 27 g 27 g 

4-Methylaminorex .................................................................................................................................... 2 g 2 g 

4-Methyl-2,5-dimethoxyamphetamine (DOM) .......................................................................................... 2 g 2 g 

5-Methoxy-3,4-methylenedioxyamphetamine .......................................................................................... 2 g 2 g 

5-Methoxy-N,N-diisopropyltryptamine ...................................................................................................... 5 g 5 g 

Acetyl-alpha-methylfentanyl ..................................................................................................................... 2 g 2 g 

Acetyldihydrocodeine ............................................................................................................................... 2 g 2 g 

Acetylmethadol ........................................................................................................................................ 2 g 2 g 

Allylprodine .............................................................................................................................................. 2 g 2 g 

Alphacetylmethadol .................................................................................................................................. 2 g 2 g 

Alpha-ethyltryptamine .............................................................................................................................. 2 g 2 g 

Alphameprodine ....................................................................................................................................... 2 g 2 g 

Alphamethadol ......................................................................................................................................... 2 g 2 g 

Alpha-methylfentanyl ............................................................................................................................... 2 g 2 g 

Alpha-methylthiofentanyl .......................................................................................................................... 2 g 2 g 

Aminorex .................................................................................................................................................. 2 g 2 g 

Benzylmorphine ....................................................................................................................................... 2 g 2 g 

Betacetylmethadol ................................................................................................................................... 2 g 2 g 

Beta-hydroxy-3-methylfentanyl ................................................................................................................ 2 g 2 g 

Beta-hydroxyfentanyl ............................................................................................................................... 2 g 2 g 

Betameprodine ......................................................................................................................................... 2 g 2 g 

Betamethadol ........................................................................................................................................... 2 g 2 g 

Betaprodine .............................................................................................................................................. 2 g 2 g 

Bufotenine ................................................................................................................................................ 3 g 3 g 

Cathinone ................................................................................................................................................. 3 g 3 g 

Codeine-N-oxide ...................................................................................................................................... 602 g 602 g 


erowe on DSK5CLS3C1PROD with NOTICES
Federal Register / Vol. 74, No. 140 / Thursday, July 23, 2009 / Notices 36513 

Basic class—schedule I 

Previously 

established initial 

2009 quotas 

Proposed revised 

2009 quotas 

Diethyltryptamine ..................................................................................................................................... 2 g 2 g 

Difenoxin .................................................................................................................................................. 3,000 g 3,000 g 

Dihydromorphine ...................................................................................................................................... 2,549,000 g 2,549,000 g 

Dimethyltryptamine .................................................................................................................................. 3 g 3 g 

Gamma-hydroxybutyric acid .................................................................................................................... 24,200,00 g 24,200,000 g 

Heroin ...................................................................................................................................................... 20 g 20 g 

Hydromorphinol ........................................................................................................................................ 2 g 2 g 

Hydroxypethidine ..................................................................................................................................... 2 g 2 g 

Ibogaine ................................................................................................................................................... 1 g 1 g 

Lysergic acid diethylamide (LSD) ............................................................................................................ 10 g 10 g 

Marihuana ................................................................................................................................................ 4,500,000 g 4,500,000 g 

Mescaline ................................................................................................................................................. 7 g 7 g 

Methaqualone .......................................................................................................................................... 5 g 5 g 

Methcathinone ......................................................................................................................................... 4 g 4 g 

Methyldihydromorphine ............................................................................................................................ 2 g 2 g 

Morphine-N-oxide .................................................................................................................................... 605 g 605 g 

N-Benzylpiperazine .................................................................................................................................. 2 g 2 g 

N,N-Dimethylamphetamine ...................................................................................................................... 7 g 7 g 

N-Ethylamphetamine ............................................................................................................................... 2 g 2 g 

N-Hydroxy-3,4-methylenedioxyamphetamine .......................................................................................... 2 g 2 g 

Noracymethadol ....................................................................................................................................... 2 g 2 g 

Norlevorphanol ......................................................................................................................................... 52 g 52 g 

Normethadone ......................................................................................................................................... 2 g 2 g 

Normorphine ............................................................................................................................................ 16 g 16 g 

Para-fluorofentanyl ................................................................................................................................... 2 g 2 g 

Phenomorphan ........................................................................................................................................ 2 g 2 g 

Pholcodine ............................................................................................................................................... 2 g 2 g 

Psilocybin ................................................................................................................................................. 7 g 7 g 

Psilocyn .................................................................................................................................................... 7 g 7 g 

Tetrahydrocannabinols ............................................................................................................................ 312,500 g 312,500 g 

Thiofentanyl ............................................................................................................................................. 2 g 2 g 

Trimeperidine ........................................................................................................................................... 2 g 2 g 

Basic class—schedule II 

Previously 

established initial 

2009 quotas 

Proposed revised 

2009 quotas 

1-Phenylcyclohexylamine ........................................................................................................................ 2 g 2 g 

1-Piperdinocyclohexanecarbonitrile ......................................................................................................... 2 g 2 g 

Alfentanil .................................................................................................................................................. 8,000 g 8,000 g 

Alphaprodine ............................................................................................................................................ 2 g 2 g 

Amobarbital .............................................................................................................................................. 3 g 3 g 

Amphetamine (for sale) ........................................................................................................................... 17,000,000 g 17,000,000 g 

Amphetamine (for conversion) ................................................................................................................ 5,000,000 g 5,000,000 g 

Cocaine .................................................................................................................................................... 247,000 g 247,000 g 

Codeine (for sale) .................................................................................................................................... 39,605,000 g 39,605,000 g 

Codeine (for conversion) ......................................................................................................................... 65,000,000 g 65,000,000 g 

Dextropropoxyphene ................................................................................................................................ 106,000,000 g 106,000,000 g 

Dihydrocodeine ........................................................................................................................................ 1,200,000 g 1,200,000 g 

Diphenoxylate .......................................................................................................................................... 947,000 g 947,000 g 

Ecgonine .................................................................................................................................................. 83,000 g 83,000 g 

Ethylmorphine .......................................................................................................................................... 2 g 2 g 

Fentanyl ................................................................................................................................................... 1,428,000 g 1,428,000 g 

Glutethimide ............................................................................................................................................. 2 g 2 g 

Hydrocodone (for sale) ............................................................................................................................ 55,000,000 g 55,000,000 g 

Hydromorphone ....................................................................................................................................... 3,300,000 g 3,300,000 g 

Isomethadone .......................................................................................................................................... 2 g 2 g 

Levo-alphacetylmethadol (LAAM) ............................................................................................................ 3 g 3 g 

Levomethorphan ...................................................................................................................................... 5 g 5 g 

Levorphanol ............................................................................................................................................. 10,000 g 10,000 g 

Lisdexamfetamine .................................................................................................................................... 6,200,000 g 6,200,000 g 

Meperidine ............................................................................................................................................... 8,600,000 g 8,600,000 g 

Meperidine Intermediate-A ...................................................................................................................... 3 g 3 g 

Meperidine Intermediate-B ...................................................................................................................... 7 g 7 g 

Meperidine Intermediate-C ...................................................................................................................... 3 g 3 g 

Metazocine ............................................................................................................................................... 1 g 1 g 

Methadone (for sale) ............................................................................................................................... 25,000,000 g 25,000,000 g 

Methadone Intermediate .......................................................................................................................... 26,000,000 g 26,000,000 g 

Methamphetamine ................................................................................................................................... 3,130,000 g 3,130,000 g 


erowe on DSK5CLS3C1PROD with NOTICES
36514 Federal Register / Vol. 74, No. 140 / Thursday, July 23, 2009 / Notices 

Basic class—schedule II 

Previously 

established initial 

2009 quotas 

Proposed revised 

2009 quotas 

[680,000 grams of levo-desoxyephedrine for use in a non-controlled, non-prescription product; 2,405,000 grams for methamphetamine mostly 

for conversion to a schedule III product; and 45,000 grams for methamphetamine (for sale)] 

Methylphenidate ....................................................................................................................................... 50,000,000 g 50,000,000 g 

Morphine (for sale) .................................................................................................................................. 35,000,000 g 35,000,000 g 

Morphine (for conversion) ........................................................................................................................ 100,000,000 g 100,000,000 g 

Nabilone ................................................................................................................................................... 9,002 g 9,002 g 

Noroxymorphone (for sale) ...................................................................................................................... 10,000 g 10,000 g 

Noroxymorphone (for conversion) ........................................................................................................... 9,000,000 g 9,000,000 g 

Opium (powder) ....................................................................................................................................... 1,050,000 g 230,000 g 

Opium (tincture) ....................................................................................................................................... 230,000 g 1,050,000 g 

Oripavine .................................................................................................................................................. 15,000,000 g 15,000,000 g 

Oxycodone (for sale) ............................................................................................................................... 77,560,000 g 77,560,000 g 

Oxycodone (for conversion) .................................................................................................................... 3,400,000 g 3,400,000 g 

Oxymorphone .......................................................................................................................................... 2,000,000 g 2,000,000 g 

Oxymorphone (for conversion) ................................................................................................................ 12,000,000 g 12,000,000 g 

Pentobarbital ............................................................................................................................................ 28,000,000 g 28,000,000 g 

Phenazocine ............................................................................................................................................ 1 g 1 g 

Phencyclidine ........................................................................................................................................... 20 g 20 g 

Phenmetrazine ......................................................................................................................................... 2 g 2 g 

Phenylacetone ......................................................................................................................................... 1 g 1 g 

Racemethorphan ..................................................................................................................................... 2 g 2 g 

Remifentanil ............................................................................................................................................. 500 g 500 g 

Secobarbital ............................................................................................................................................. 67,000 g 67,000 g 

Sufentanil ................................................................................................................................................. 10,300 g 10,300 g 

Tapentadol 1 ............................................................................................................................................. 0 g 519,000 g 

Thebaine .................................................................................................................................................. 126,000,000 g 126,000,000 g 

1Tapentadol was placed in schedule II of the Controlled Substances Act by a final order published by the Drug Enforcement Administration on 

May 21, 2009 (74 FR 23790). 

The Deputy Administrator further 

proposes that aggregate production 

quotas for all other schedules I and II 

controlled substances included in 21 

CFR 1308.11 and 1308.12 remain at 

zero. 

All interested persons are invited to 

submit their comments in writing or 

electronically regarding this proposal 

following the procedures in the 

ADDRESSES section of this document. A 

person may object to or comment on the 

proposal relating to any of the abovementioned substances without filing 

comments or objections regarding the 

others. If a person believes that one or 

more of these issues warrant a hearing, 

the individual should so state and 

summarize the reasons for this belief. 

Persons wishing to request a hearing 

should note that such requests must be 

written and manually signed; requests 

for a hearing will not be accepted via 

electronic means. 

In the event that comments or 

objections to this proposal raise one or 

more issues which the Deputy 

Administrator finds warrant a hearing, 

the Deputy Administrator shall order a 

public hearing by notice in the Federal 

Register, summarizing the issues to be 

heard and setting the time for the 

hearing as per 21 CFR 1303.13(c). 

Regulatory Certifications 

Regulatory Flexibility Act 

The Deputy Administrator hereby 

certifies that this action will not have a 

significant economic impact upon small 

entities whose interests must be 

considered under the Regulatory 

Flexibility Act, 5 U.S.C. 601–612. The 

establishment of aggregate production 

quotas for schedules I and II controlled 

substances is mandated by law and by 

international treaty obligations. The 

quotas are necessary to provide for the 

estimated medical, scientific, research 

and industrial needs of the United 

States, for lawful export requirements, 

and the establishment and maintenance 

of reserve stocks. While aggregate 

production quotas are of primary 

importance to large manufacturers, their 

impact upon small entities is neither 

negative nor beneficial. Accordingly, the 

Deputy Administrator has determined 

that this action does not require a 

regulatory flexibility analysis. 

Executive Order 12866 

The Office of Management and Budget 

has determined that notices of aggregate 

production quotas are not subject to 

centralized review under Executive 

Order 12866. 

Executive Order 13132 

This action does not preempt or 

modify any provision of state law; nor 

does it impose enforcement 

responsibilities on any state; nor does it 

diminish the power of any state to 

enforce its own laws. Accordingly, this 

action does not have federalism 

implications warranting the application 

of Executive Order 13132. 

Executive Order 12988 

This action meets the applicable 

standards set forth in Sections 3(a) and 

3(b)(2) of Executive Order 12988 Civil 

Justice Reform. 

Unfunded Mandates Reform Act of 

1995 

This action will not result in the 

expenditure by state, local, and tribal 

governments, in the aggregate, or by the 

private sector, of $120,000,000 or more 

(adjusted for inflation) in any one year, 

and will not significantly or uniquely 

affect small governments. Therefore, no 

actions were deemed necessary under 

the provisions of the Unfunded 

Mandates Reform Act of 1995. 

Congressional Review Act 

This action is not a major rule as 

defined by Section 804 of the Small 

Business Regulatory Enforcement 

Fairness Act of 1996 (Congressional 

Review Act). This action will not result 

in an annual effect on the economy of 

$100,000,000 or more; a major increase 

in costs or prices; or significant adverse 

effects on competition, employment, 


erowe on DSK5CLS3C1PROD with NOTICES
Federal Register / Vol. 74, No. 140 / Thursday, July 23, 2009 / Notices 36515 

1For purposes of this proposed exemption, 

references to specific provisions of Title I of the 

Act, unless otherwise specified, refer also to the 

corresponding provisions of the Code. 

investment, productivity, innovation, or 

on the ability of United States-based 

companies to compete with foreignbased companies in domestic and 

export markets. 

Dated: July 16, 2009. 

Michele M. Leonhart, 

Deputy Administrator. 

[FR Doc. E9–17536 Filed 7–22–09; 8:45 am] 

BILLING CODE 4410–09–P 

DEPARTMENT OF JUSTICE 

Foreign Claims Settlement 

Commission 

F.C.S.C. Meeting Notice No. 4–09 

The Foreign Claims Settlement 

Commission, pursuant to its regulations 

(45 CFR Part 504) and the Government 

in the Sunshine Act (5 U.S.C. 552b), 

hereby gives notice in regard to the 

scheduling of meetings for the 

transaction of Commission business and 

other matters specified, as follows: 

Date and Time: Tuesday, July 28, 

2009, at 11 a.m. 

Subject Matter: Issuance of Proposed 

Decisions in claims against Albania and 

Libya. 

Status: Open. 

All meetings are held at the Foreign 

claims Settlement Commission, 600 E 

Street, NW., Washington, DC. Requests 

for information, or advance notices of 

intention to observe an open meeting, 

may be directed to: Administrative 

Officer, Foreign Claims Settlement 

Commission, 600 E Street, NW., Room 

6002, Washington, DC 20579. 

Telephone: (202) 616–6975. 

Dated at Washington, DC. 

Mauricio J. Tamargo, 

Chairman. 

[FR Doc. E9–17443 Filed 7–22–09; 8:45 am] 

BILLING CODE 4410–01–P 

DEPARTMENT OF LABOR 

Employee Benefits Security 

Administration 

[Application No. and Proposed Exemption 

Involving: Bank of New York Mellon 

Corporation, D–11553] 

Notice of Proposed Exemption 

AGENCY: Employee Benefits Security 

Administration, Labor. 

ACTION: Notice of proposed exemption. 

SUMMARY: This document contains a 

notice of pendency before the 

Department of Labor (the Department) of 

a proposed exemption from certain of 

the prohibited transaction restrictions of 

the Employee Retirement Income 

Security Act of 1974 (ERISA or the Act) 

and/or the Internal Revenue Code of 

1986 (the Code). 

Written Comments and Hearing 

Requests 

All interested persons are invited to 

submit written comments or requests for 

a hearing on the pending exemption, 

unless otherwise stated in the Notice of 

Proposed Exemption, within 45 days 

from the date of publication of this 

Federal Register Notice. Comments and 

requests for a hearing should state: (1) 

The name, address, and telephone 

number of the person making the 

comment or request, and (2) the nature 

of the person’s interest in the exemption 

and the manner in which the person 

would be adversely affected by the 

exemption. A request for a hearing must 

also state the issues to be addressed and 

include a general description of the 

evidence to be presented at the hearing. 

ADDRESSES: All written comments and 

requests for a hearing (at least three 

copies) should be sent to the Employee 

Benefits Security Administration 

(EBSA), Office of Exemption 

Determinations, Room N–5649, U.S. 

Department of Labor, 200 Constitution 

Avenue, NW., Washington, DC 20210. 

Attention: Application No. D–11553. 

Interested persons are also invited to 

submit comments and/or hearing 

requests to EBSA via e-mail or FAX. 

Any such comments or requests should 

be sent either by e-mail to: 

moffitt.betty@dol.gov, or by FAX to 

(202) 219–0204 by the end of the 

scheduled comment period. The 

application for exemption and the 

comments received will be available for 

public inspection in the Public 

Documents Room of the Employee 

Benefits Security Administration, U.S. 

Department of Labor, Room N–1513, 

200 Constitution Avenue, NW., 

Washington, DC 20210. 

Notice to Interested Persons 

Notice of the proposed exemption 

will be provided to all interested 

persons in the manner agreed upon by 

the applicant and the Department 

within 15 days of the date of publication 

in the Federal Register. Such notice 

shall include a copy of the notice of 

proposed exemption as published in the 

Federal Register and shall inform 

interested persons of their right to 

comment and to request a hearing 

(where appropriate). 

SUPPLEMENTARY INFORMATION: The 

proposed exemption was requested in 

an application filed pursuant to section 

408(a) of the Act and/or section 

4975(c)(2) of the Code, and in 

accordance with procedures set forth in 

29 CFR Part 2570, Subpart B (55 FR 

32836, 32847, August 10, 1990). 

Effective December 31, 1978, section 

102 of Reorganization Plan No. 4 of 

1978, 5 U.S.C. App. 1 (1996), transferred 

the authority of the Secretary of the 

Treasury to issue exemptions of the type 

requested to the Secretary of Labor. 

Therefore, this notice of proposed 

exemption is issued solely by the 

Department. 

The application contains 

representations with regard to the 

proposed exemption which is 

summarized below. Interested persons 

are referred to the application on file 

with the Department for a complete 

statement of the facts and 

representations. 

Bank of New York Mellon Corporation 

Located in Pittsburgh, PA 

[Application No. D–11553] 

Proposed Exemption 

The Department is considering 

granting an exemption under the 

authority of section 408(a) of the Act 

and section 4975(c)(2) of the Code and 

in accordance with the procedures set 

forth in 29 CFR part 2570, subpart B (55 

FR 32836, 32847, August 10, 1990). 

If the proposed exemption is granted, 

the restrictions of sections 406(a)(1)(A) 

through (D), 406(b)(1) and 406(b)(2) of 

the Act and the sanctions resulting from 

the application of section 4975 of the 

Code, by reason of section 4975(c)(1)(A) 

through (E) of the Code,1 shall not 

apply, effective November 25, 2008, to 

the cash sale of certain securities (the 

Securities) issued by Lehman Brothers 

Holdings Inc. or its affiliates (Lehman) 

for an aggregate purchase price of 

approximately $5,512,395 by the EB 

SMAM Securities Lending Temporary 

Investment Fund (the Cash Collateral 

Fund) to the Bank of New York Mellon 

Corporation (BNYMC), a party in 

interest with respect to the employee 

benefit plans (the Plan(s)) invested, 

directly or indirectly, in the Cash 

Collateral Fund; provided that the 

following conditions are met: 

(a) The sale of the Securities was a 

one-time transaction for cash; 

(b) The Cash Collateral Fund received 

an amount for the sale of the Securities 

which was equal to the sum of: 

(1) the amortized cost of the 

Securities, and (2) the accrued but 


erowe on DSK5CLS3C1PROD with NOTICES